Analyst and Investor Call to

Dec 17, 2021 · potential efficacy against variants and variant specific vaccine development and anticipated manufacturing, distribution, supply, revenue contribution, growth and performance); Pfizer’s investigational oral antiviral candidate PAXLOVID (including qualitative assessments of available data, including interim data,

  Variant